Although RNAi had long been a key aspect of Opko's technology portfolio, the failure of its AMD drug in phase III and a series of recent investments in other technologies raises questions about its interest in siRNA drugs.
Phillip Sharp, Jamie Freedman
According to an Opko filing with the US Securities and Exchange Commission, it settled the litigation without admitting wrongdoing in order to "avoid the expense and uncertainty of litigation."
Unlike other biotechs facing a cash crunch, Opko's chief executive and biggest investor is a billionaire who has used his wealth before to keep the company afloat.
Although the future of the drug is unclear, an Opko executive said that the firm remains committed to its portfolio of VEGF-targeting siRNAs.
Alnylam Pharmaceuticals, Opko Health, Australian Patent Office
An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.
An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.
In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.
Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.